Patents by Inventor David John Morgans, Jr.
David John Morgans, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11976067Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.Type: GrantFiled: January 17, 2023Date of Patent: May 7, 2024Assignee: Maze Therapeutics, Inc.Inventors: Patrick Sang Tae Lee, Todd Jonathan August Ewing, Adam Neil Reid, Christopher Joseph Sinz, Birong Zhang, Sarah M. Bronner, David John Morgans, Jr., Maarten Hoek, Victoria Anne Assimon, Chris Ziebenhaus, Alexander Wayne Schammel
-
Publication number: 20240043421Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSW).Type: ApplicationFiled: February 27, 2023Publication date: February 8, 2024Inventors: David John MORGANS, JR., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
-
Publication number: 20230406803Abstract: Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia, Ib, IIa, IIb, or IIc and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising said compounds or tautomers. The present disclosure further relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia, Ib, IIa, IIb, or IIc compounds or tautomers.Type: ApplicationFiled: October 16, 2020Publication date: December 21, 2023Applicant: Kinesid Therapeutics, IncInventors: Jianhua Chao, Gustave Bergnes, Kevin T Mellen, David John Morgans, JR., Stanley J Hollenach, Douglas M Matje, Nicholas M Snead, Michael Christopher Holmes
-
Publication number: 20230365556Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.Type: ApplicationFiled: April 27, 2023Publication date: November 16, 2023Applicant: Pliant Therapeutics, Inc.Inventors: Lan JIANG, David John MORGANS, JR., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall L. HALCOMB, Jacob CHA, Timothy HOM
-
Patent number: 11814367Abstract: Provided herein are compounds of formula (I?): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rn are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I?). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.Type: GrantFiled: March 14, 2022Date of Patent: November 14, 2023Assignee: MAZE THERAPEUTICS, INC.Inventors: David John Morgans, Jr., Kevin Mellem, Hannah L. Powers, Patrick Sang Tae Lee, Walter Won, Christopher Joseph Sinz
-
Publication number: 20230271960Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: ApplicationFiled: December 19, 2022Publication date: August 31, 2023Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, Manuel MUNOZ, David John MORGANS, JR., Maureen REILLY, Yajun ZHENG, Christopher BAILEY, Darren FINKELSTEIN
-
Publication number: 20230265096Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.Type: ApplicationFiled: January 17, 2023Publication date: August 24, 2023Inventors: Patrick Sang Tae LEE, Todd Jonathan August EWING, Adam Neil REID, Christopher Joseph SINZ, Birong ZHANG, Sarah M. BRONNER, David John MORGANS, Jr., Maarten HOEK, Victoria Anne ASSIMON, Chris ZIEBENHAUS, Alexander Wayne SCHAMMEL
-
Patent number: 11673887Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.Type: GrantFiled: March 4, 2020Date of Patent: June 13, 2023Assignee: Pliant Therapeutics, Inc.Inventors: Lan Jiang, David John Morgans, Jr., Gustave Bergnes, Chun Chen, Hui Li, Patrick Andre, Randall Halcomb, Jacob Cha, Timothy Hom
-
Patent number: 11634418Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: GrantFiled: June 5, 2020Date of Patent: April 25, 2023Assignee: Pliant Therapeutics, Inc.Inventors: David John Morgans, Jr., Randall L. Halcomb, Gustave Bergnes, Hui Li, Lan Jiang, Jacob Cha, Timothy Hom
-
Publication number: 20230104740Abstract: Provided herein are compounds of formula (I?): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rn are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I?). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.Type: ApplicationFiled: March 14, 2022Publication date: April 6, 2023Inventors: David John MORGANS, JR., Kevin MELLEM, Hannah L. POWERS, Patrick Sang Tae LEE, Walter WON, Christopher Joseph SINZ
-
Patent number: 11560376Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: GrantFiled: June 26, 2020Date of Patent: January 24, 2023Assignee: Pliant Therapeutics, Inc.Inventors: Jacob Cha, Chengguo Dong, Timothy Hom, Lan Jiang, Katerina Leftheris, Hui Li, David John Morgans, Jr., Manuel Munoz, Maureen Reilly, Yajun Zheng, Christopher Bailey, Darren Finklestein
-
Publication number: 20210122747Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8. X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: ApplicationFiled: June 5, 2020Publication date: April 29, 2021Inventors: David John MORGANS, Jr., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
-
Publication number: 20210024516Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.Type: ApplicationFiled: March 4, 2020Publication date: January 28, 2021Inventors: Lan JIANG, David John MORGANS, Jr., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall HALCOMB, Jacob CHA, Timothy HOM
-
Publication number: 20210017171Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: ApplicationFiled: June 26, 2020Publication date: January 21, 2021Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David John MORGANS, JR., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG
-
Patent number: 10696672Abstract: The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: GrantFiled: December 20, 2017Date of Patent: June 30, 2020Assignee: Pliant Therapeutics, Inc.Inventors: David John Morgans, Jr., Randall L. Halcomb, Gustave Bergnes, Hui Li, Lan Jiang, Jacob Cha, Timothy Hom
-
Patent number: 10604520Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.Type: GrantFiled: September 7, 2017Date of Patent: March 31, 2020Assignee: Pliant Therapeutics, Inc.Inventors: Lan Jiang, David John Morgans, Jr., Gustave Bergnes, Chun Chen, Hui Li, Patrick Andre, Randall L. Halcomb, Jacob Cha, Timothy Hom
-
Publication number: 20190322663Abstract: The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: ApplicationFiled: December 20, 2017Publication date: October 24, 2019Inventors: David John MORGANS, Jr., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
-
Publication number: 20180093984Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.Type: ApplicationFiled: September 7, 2017Publication date: April 5, 2018Inventors: Lan JIANG, David John MORGANS, JR., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall L. HALCOMB, Jacob CHA, Timothy HOM
-
Patent number: 5688795Abstract: The present invention relates to novel .alpha..sub.1 -adrenoceptor antagonists of Formula I: ##STR1## in which: p is 0 or 1;t is 0, 1 or 2;X is O, S or NR.sup.6 (in which R.sup.6 is hydro or (C.sub.1-6)alkyl);Y and Z are independently CH or N;R.sup.1 is hydro, hydroxy, halo, nitro, amino, cyano, (C.sub.1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C.sub.1-4)alkyl, heteroaryl (C.sub.1-4)alkyl, (C.sub.1-6)alkyloxy, (C.sub.3-6)cycloalkyloxy, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C.sub.1-4)alkyloxy or heteroaryl (C.sub.1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano);R.sup.2 is hydro, hydroxy, halo, cyano, (C.sub.1-6)alkyl or (C.sub.Type: GrantFiled: November 8, 1994Date of Patent: November 18, 1997Assignee: Syntex (U.S.A.) Inc.Inventors: Jurg Roland Pfister, David Ernest Clarke, Todd Richard Elworthy, David John Morgans, Jr., David Bruce Repke, Eric Brian Sjorgren, Helen Yen-hui Wu